Article Details
Retrieved on: 2025-06-07 17:36:03
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Immix Biopharma's current full-year earnings is ...
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here